Chou, Yu-Chi

YCChou6x7Assistant Research Scientist


E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: (Office) 02-2787-1239 | (Lab) 02-2789-8763 ext 16

 

EDUCATION AND POSITIONS HELD:

  • B.Sc., Department of Plant Pathology and Microbiology, National Taiwan University, Taiwan, 1992-1996
  • M.Sc., Microbiology and Immunology, National Yang-Ming University, Taiwan, 1996-1998
  • Ph.D., Microbiology and Immunology, National Yang-Ming University, Taiwan, 1998-2004
  • Postdoctoral Fellow, Institute of Molecular Biology, Academia Sinica, Taiwan, 2005-2016
  • Assistant Manager, National RNAi Core Facility Platform, Academia Sinica, Taiwan, 2013-2015
  • Manager, Core Facility for Manipulation of Gene Function by RNAi, miRNA, miRNA sponges, and CRISPR (C6 core facility), Academia Sinica, Taiwan, 2015-present
  • Assistant Research Scientist, Genomics Research Center, Academia Sinica, Taiwan, 2016-present

HONORS:

  • Outstanding Academic Paper Award, Liver Disease Prevention and Treatment Research Foundation, Taiwan, 2005
  • Special Award for Academic Research of Hepatitis B Virus, Liver Disease Prevention and Treatment Research Foundation, Taiwan, 2008

PATENTS:

  • RREB1 as A Target for Therapy of Thalassemias and Sickle Cell Anemia. US 13/008,279; TW I432730; Inventors: Chou YC, Chen RL and Shen CK
  • Novel Compounds for Therapy of β-Thalassemia and Sickle Cell Disease. US 8,822,491; EP 12747213.2; CN 201280009511.9; TW I466,670 (Technology transfer to PharmaEssentia Crop.; NT 20,000,000); Inventors: Chou YC and Shen CK
  • N-substituted 1,8-naphthalimide derivatives are potential compounds for treating β-thalassemia and sickle cell disease. US 14/787,885; TW I536,993; CN 2013800638764 (Technology transfer in preparation); Inventors: Chou YC, Su TL and Shen CK

FACILITY MANAGEMENT / EXPERTISE:

We devote to provide various gene manipulating reagents, including RNAi, miRNA, miRNA sponges and CRISPR/Cas resources, for researchers. This core facility can perform genome-scale or small-scale pooled screenings by using RNAi, miRNA or CRISPR/Cas resource. We can assist the establishment of cell lines with gene knockout or knock-in by CRISPR/Cas techniques. Moreover, we also perform MOA studies for high-throughput screenings carried out by small-molecule platforms and antibody phage display platforms.

SELECTED PUBLICATIONS: